Life Sciences Newsroom



Back to List

New-Legislation-Concerning-Falsified-Medicines

06 Nov 2012 | Fiona Luciani

The European Union (EU) Falsified Medicines Directive amends Directive 2001/83/EC to safeguard public health by protecting the pharmaceutical supply chain from infiltration by falsified (or counterfeit) medicines and introduces new rules to more rigorously regulate the supply chain.

The Irish Medicines Board (IMB) today have issued new content in relation to New legislation concerning falsified medicines.

They have updated their website as follows:


The European Union (EU) Falsified Medicines Directive amends Directive 2001/83/EC to safeguard public health by protecting the pharmaceutical supply chain from infiltration by falsified (or counterfeit) medicines and introduces new rules to more rigorously regulate the supply chain. The main provisions of the 
Falsified Medicines Directive are:

  • To introduce a new obligatory authenticity feature (referred to as a safety feature) which must appear on the outer packaging of designated medicines,
  • To introduce more robust rules regarding the control on starting materials and inspection of producers of active substances and excipients contained in medicines,
  • To introduce more robust controls on the wholesale distribution of medicines, including introducing controls for the first time on entities involved in brokering medicines,
  • To introduce a common, EU-wide logo to identify legal online pharmacies and to establish a notification system for entities offering to supply medicines to the public over the internet.

The falsified medicines legislative proposal was adopted by the Council and European Parliament in June 2011. The deadline for transposition of the Directive is January 2nd 2013.

Directive 2011/62/EC provides the basis of a number of implementation measures by the Commission. An overview is provided
here.

The IMB is working with a wide range of stakeholders, including the Department of Health, Customs and Excise, European Medicines Agency, European Commission and other national competent authorities on the implementation of the provisions contained within the new legislation.


New rules on importing active pharmaceutical ingredients into the European Union

The European Commission has published an information leaflet on the
new rules on importing active pharmaceutical ingredients into the European Union.

The IMB is conducting a survey of active substances that are used by medicinal product manufacturers in Ireland that are produced outside of the EEA.

My Account

Please enter your username and password and click login